` CANF (Can Fite Biopharma Ltd) vs Tel Aviv 355 Comparison - Alpha Spread

C
CANF
vs
T
Tel Aviv 355

Over the past 12 months, CANF has underperformed Tel Aviv 355, delivering a return of -47% compared to the Tel Aviv 355's +54% growth.

Stocks Performance
CANF vs Tel Aviv 355

Loading
CANF
Tel Aviv 355
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
CANF vs Tel Aviv 355

Loading
CANF
Tel Aviv 355
Difference
www.alphaspread.com

Performance By Year
CANF vs Tel Aviv 355

Loading
CANF
Tel Aviv 355
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Can Fite Biopharma Ltd vs Peers

Tel Aviv 355
CANF
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Can Fite Biopharma Ltd
Glance View

Market Cap
78.6m ILS
Industry
Biotechnology

Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The firm co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.

CANF Intrinsic Value
3.03 ILS
Undervaluation 67%
Intrinsic Value
Price
C
Back to Top